Asian Journal of Medical and Pharmaceutical Sciences
ISSN: 2348-0165
Journal Home Page: www.pharmaresearchlibrary.com/ajmps



Nanocarrier Based Approaches for the Treatment of Psoriasis: Opportunities and Challenges

Deepa Lashkari*

Amity University Jaipur Campus SP-1, Kant Kalwar, RIICO Industrial Area, NH-11C, Jaipur, Rajasthan

A B S T R A C T

Psoriasisis a chronic, incurable, autoimmune skin disorder characterized by significant negative physical and emotional collisions as constant relapsing inflammatory and proliferative disease that influence roughly around 3.6% of the US population. The etiopathogenesis of Psoriasis is not known fully but the novel therapies are developed which not only provide better therapeutic effect, good physical stability, high entrapment of efficiency of lipophilic drugs as well as for hydrophilic drugs, low drug dosing. Nowadays these novel therapies provide successful depletion of Psoriatic skin in case of moderate to severe Psoriatic patients but it is not developed to cure the disease permanently and these novel therapies provide a new challenge and provide low-cost efficacy of drugs, good bioavailability for the treatment of Psoriasis.

Keywords: - Psoriasis, novel drug delivery system, etiopathogenesis, treatment approaches, targeting sites.

A R T I C L E I N F O

Corresponding Author
Deepa Lashkari
Amity University Jaipur Campus SP-1,
Kant Kalwar, RIICO Industrial Area,
NH-11C, Jaipur, Rajasthan
MS-ID:AJMPS4191

JOURNAL QR-CODE

A R T I C L E H I S T O R Y: Received 21 Dec 2019, **Accepted** 18 February 2020, **Available Online** 19 June 2020

© 2020 *Production and hosting by Asian Journal of Medical and Pharmaceutical Sciences, All rights reserved.*

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Citation: *Deepa Lashkari, et al.* Nanocarrier Based Approaches for the Treatment of Psoriasis: Opportunities and Challenges.*A. J. Med. Pharm, Sci.*, 2020, 8(1): 16-31.

C O N T E N T S

1. Introduction

Psoriasis is a recurrent, cureless, autoimmune skin disarrangement identified by representational negative physical andemotional collisions as constant worsening inflammatory and reproducible disease that bought influences approximately 3.6% of the US population (Kruger J.G et.al, 2002; Lebwohl M et.al, 1995; T. Mabuchi et.al, 2012). It is clear as the disease broadly documented to be caused by the group working jointly in association with genetic and environmental aspect equally trauma, drugs, infection, alcohol, smoking, and stress but its exact source is yet no more identified(M. Pradhan et.al,2013).In India, it financial substantiation for about 2.3% of figure up dermatology outpatients. It universally begins at intervals the ages of 20 and 40 years with an average age of

beginning at 27 years(Md. Sarfaraz et.al, 2016 &Bhalerao J et.al, 1995).It can be characterized by itchy and painful red scaly skin. The generally frequently pretentious areas are the entire scalp and in addition it also spreads to the forehead, back of the neck or behind ears, chest, arms, and elbows, in the armpits, under the breasts, around the genitals, knees, legs, toenails, and fingernails. It affects males and females likewise and moreover affects children, adult, older natives and may take place at any age of life. The words Psoriasis roll up from the Greek word "**Psora"** which means **"itching"**. It is a period which has been in used since 133 AD and was at the beginning grouped with leprosy until the 19th century. It has been optional that biblical leprosy was, in a piece of information the disorder in the present day acknowledged as Psoriasis(Ram, 2013).Among these, **chronic plaque psoriasis (CPP)** symbolizesforemost disease with analogouspossibility in both sexes and initial beginning prior to the era of 40 years(Henning Wolf et.al, 2015). It is greater in common people between the ages of 15 and 35, according to National Psoriasis Foundation(Kuchekar et.al, 2011). It leads to deep speculation to be caused by hyperproliferation of keratinocytes. It can range from mild to severe condition. However, the arrangement can be done into four distinct types such as guttate, pustular, erythrodermic and inverse psoriasis. The proportion of the body damaged by psoriatic plaques can show a discrepancyi.e. in case of mild psoriasis less than 2%, moderate between 2-10% and severe greater than10% people are affected. The cause of psoriasis is not fully established but it is thought to be believed that multifactorial involving both genetic and inflammatory disorder (Ewout Baer veldt, 2013).

The particular beginning or exact etiopathogenesis of Psoriasis is now new, indicating contrast, it appears to be brought about through a number appropriate to their families based on genetic traits and environmental features like alcohol, tobacco, infections, medications, stress. In Psoriatic patients, the identification of the disease is hardly restrained. It is relatively the manner on the superiority of life which is unstable. The first indication of psoriasis may take place at any age. Its length of action may contrast from a hardly any weeks to a total go time. The course is uncertain and showed distinct deviation. The most characteristic abrasion consisting of never-ending, strongly delimit, dull-red, scaly plaques, particularly on the extensor prominences and in the scalp. Nail changes mightshowedindication about the growth of Psoriasis in a different place, or stay onconfined to a small area for definite lifetime. The appearance of a typical abrasion is characteristic. These plaques are one to several centimetres, different in diameter and are oval or uneven in shape. There can be a small number of abrasions or singly or multiples may be equitablydispersed. Common clinical types are chronic plaque-type psoriasis (psoriasis vulgaris) and psoriatic arthritis(Sarah Dubois et.al, 2013). Four distinct pathological features are characteristics of psoriasis as follows:

- ✓ Epidermis Hyperprolifration. Transformed maturation of the epidermis (resulting in scaling)
- ✓ **Inflammation**
- ✓ **Vascular modification (resulting in redness)**

Even though there was a continued progress towards the explanation of the genetic and pathophysiological pathways involved in psoriasis, an alternative cure for this disease remains inconvincible. The long suffering with psoriasis disease represents a cooperation challenge and opening for drug treatment.Although, there are numerous treatments available that can provide efficient exoneration in a high percentage of psoriatic patients. For patients temperate to bearable psoriasis, the topical therapeutic report includes emollients and moisturizers, tars, anthralins, topical corticosteroids, and vitamin D analogs. On the other hand 30% of patients in quest of this handling for Psoriasis are defective and for this complete systemic therapies are required. Systemic therapies are methotrexate, acitretin, cyclosporine A, hydroxyurea, PUVA (psoralens+ UVA) with or without various topical therapies obtainable for moderate to severe patients. But these therapies are associated possibly with severe toxicity, need numerous controls and are costly and sometimes there is difficulty in administration.PUVA therapy having a long-term risk of increased skin cancers, extensive photodamage and is not acceptable for the treatment of psoriasis in pregnancy, children, and patients connected with diseases having toxicity in organs like hepatic, renal failure, ocular diseases etc. After all, these are local, systematic approaches. Moreover, the presentlyobtainable systemic therapies are chieflyoppressiveslightly than resistive, demanding permanent use, which is puzzling &given the increasing toxicities (Uva et.al, 2012).

At present time healing option for psoriasis are effectual just to cease the disease progress greater thanjust before complexities alike higher wrecked and to alleviate experimental symptoms. No investigation is accepted to make well psoriasis other than the excellence of life is embellish or improved. But during the concluding decades, innovative anti-psoriatic therapies which begun around the marketplace contains monoclonal antibodies targeting for distinct receptors currently available in psoriasis physiopathology. Presently, a lot of scientists showed up evolution in the **Innovative skin drug delivery systems (ISDDS)** which provide improved skin penetration of long term established drugs and there wereterrificdownturn in the control dose and therefore shows a greater downturn in their side effects. At this time the report deals with Psoriasis, there were great centre of attraction on the closing mechanistic observations affecting particularly immunological distress in skin abrasions and also in Psoriatic arthritis. Long-term established remedies are displayed and improved. At this point, an effort is given a global vision to the various innovative skin drug delivery systems (ISDDS) for future prospect which was developed during these last years from 2014 to 2018 to enhance skin drug delivery(Su et.al,2008). As per WHO report, there has been incremental research exploration on treatment of psoriasis as depicted in Figure.



Figure 1

Data for publication of Treatment for Psoriasis:

With the prevalence of Psoriasis disease, there were many publications of articles on Psoriasis which gives the full detail for their treatment especially for Psoriatic plaques and Psoriatic arthritis which is common nowadays and all age grouped people are affected globally. These articles provide information about the treatment but it doesn't provide the complete cure, as its pathology remains unclear. Soa graph for number of articles for Psoriasis treatment has been shown in the figure:



Figure 2

2. Pathophysiology of Psoriasis

Any drug development

The etiopathogenesis of psoriasis still remains unclear. Amassing of deceased cells on themembrane result of shortcoming tension occuring in the natural period of replacement of venerable membrane cells in the midst of freshen ones is the majorroot of Psoriasis(Picardli et al 2013).It is distinguished as a T-cell-mediated disorder in which abundant amount of T-cells inside the psoriatic membranecomprisesatriggered phenotype; CD4 T-cells also containwell-knowncells uniformly scattered randomly inside the epidermis and dermis while CD8 T-cells inhabited as a choice in the epidermis(Miteva, 2011). The origin of Psoriasis may include various factors such as inheritance, gene alteration, climate, pressure, activates infection and skin wound(Gordon-Elliott and Muskin 2013), (Fraga et al. 2012). Basically there are three events that occurred in Psoriasis(Garg et al, 2015).

1. **Stimulation of T-cell** – Human leucocyte antigen (HLA-1, HLA-4, & HLA-6) enters the human membrane& stimulates APCs. The stimulated clusters of cellsattain skin related lymphoid tissue.
2. **Immigration of stimulated T-cell into the skin** – The stimulated T-cell convey CLA factor, work together through E & P selectin express through the vascular endothelium that experiences dischargingthe membrane & migrates within the membrane inner & and outer layer.
3. **Rejuvination of T-cells inside inner & outer membrane** – These triggered T-cells experiences rejuvinationsinside the lymph nodes emergingwithin the arrangement of memory T cells, thatturn out type 1 and type 2 cytokines. Type 1 cytokines (tumor necrosis factor – α, interleukin (IL-2), interferon –γ) and type -2 cytokines (IL-4, IL-5, and IL-10) are chiefinto Psoriatic plaques & are liable, used for the evolution of fresh psoriatic abrasions.

However, the aetiology remains unclear but recent researches of Psoriasis pathophysiology there are different T-helper cells subset stated that was noticeable with Th1 & Th2 cells, which have been elaborated within the pathogenesis of Psoriasis(Garg et al,2015 & Langley et.al,2005). Likewise IL-23, a negotiation of IL-12 family which contains a p40 subunit with IL-12, which promote the growth of Th17 helper cells and the cytokines formed by Th17 cells include IL-17A, IL-17F, tumor necrosis factor alpha (TNF-α), IL-21 & IL-22 also help during the stimulus of inflammation, and help in declining of acanthosis, inflammatory permeation & reduces the appearance of Th17 cytokines(Di Cesare A, et.al, 2009). The results recommend with the aim appertaining to IL-22 is obligatory in favour of the growth appertaining to autoreactive Th17 cell defenceless disorder in the miniature of membranesoreness (Fitch E et.al, 2007).

Report for Psoriasis for inflammation concluded that the therapy of Interleukin -12/23 monoclonal antibody has proved its curativeefficiencythroughrequisite for the p40 subunit of Human interleukin 12 & 23 counteract their bioactivity besides blocking interactions through their cell-surface receptors(Iwakura Y et.al, 2006; Kauffman et.al, 2004). One of the reports illustrate that the evaluation of unit cells and cytokines prove inflated intensity of T helper cells Th1 cytokines IFN-γ, TNF-α& IL-12 are currently available in Psoriasis, except the T helper Th-2 cyt produces IL-4(Gottlieb et.al,2005), IL-5 or IL-10(Barrie et.al,2005)thatcome into view to be watchful next to psoriasis are not present and the benefit of Th2-type cytokines produces IL-4 & IL-10that have been used in experimentaltest as management for psoriasis and recommends a greater modification of the cytokine on or after Th1 to Th2 response mightlead tooverturn Psoriasis soreness due to observational changes in Psoriasiswhich ultimately brought anobservationto facilitate Psoriasis is a Th1-type disease (Ghoreschi et al.,2003).

Rahman et al. (2014) showed that the Psoriasis pathophysiology is not only caused by three factors but other factors like stress, endogenous & exogenous stimuli which ultimately brings inflammation in the skin and this has brought many challenges in today's era.Anti-psoriatic drugs for Psoriasis have been developed to a great distant and its used inpharmacotherapy to treat such skin diseases. However, nanomedicine was developed, a drug carrier

providesan impressive action including curativeefficiency with less toxicity by dose reduction, drug localization, and drug targeting. The four distinct pathological pathways are: (A) Exogenous & endogenous stimuli activation which produces reactive oxygen species in anomalous amounts, bought oxidative stress, which turn on the JAK-STAT pathway, its dimerized forms, administer gene expression and inflammation in psoriasis. (B) Intrusion of antigen to MHC of APC to form complex, which immigrate to the lymph nodes and triggered number of T cells. These ultimately go to blood vessels, shift to the epidermis and discharge cytokines, which encourage keratinocyte hyperproliferation. (C) Phospholipase A2 action on phospholipid cell membrane to produce Arachidonic acid (AA), the further action of COX and lipoxygenase onto AA, results in the production of PGs and LTs, which are responsible for inflammation in psoriasis and also induce ILs secretion. (D) Various enzymes (NADPH-dependent peroxidase and myeloperoxidase, etc.) act to cause lipid peroxidation and produce oxidized LDL (OX-LDL) and thio compounds. Higher amounts lead to induce immune inflammatory events; in another pathway also activate peroxisome PPAR-d and nuclear receptor, which ultimately produce inflammation in psoriasis.Figure 1 shows different pathways in the development of Psoriasis which can be improved by the use of nanocarriers to treat such diseases.



Figure 3: Different pathways in the pathogenesis of psoriasis

[APC: Antigen-presenting cells; LDL: Low-density lipoprotein; LTs: Leukotrienes; PG: Prostaglandins; PPAR: Proliferators activated receptor; ROS: Reactive oxygen species; COX: Cyclooxygenase; LOX: Lipoxygenase; OX-LDL: Oxidised LDL.]

Inflammation process

Role of TNF-α: The crucial role of TNF-α inhibitors etanercept(Asadullah K et.al,1999), infliximab(Lew W et.al,2004)& adalimumab(Leonardi CL et.al,2003) thatobstruct the synergy of stable TNF-αthroughTNF-α receptors on top of marked cells are extremely generous within the management of Psoriasis but finding out the revolutionary transition with inflammatory cytokines and chemokines brought about via etanercept for the management of psoriatic lesions, it have also been implied a well-known TNF-α might sturdily readjust premature cytokine manufacturing and hold up the inflammation compelled by IFN-γ and the warning sign transducer, activator of transcription (STAT) pathways, by this means reassuring chemokinescreationso as to govern T-cells and DC synergy in the skin. These TNF-α has been correlated to fatigue and depression(Chaudhary et.al, 2001). Therefore, biological therapies aimed and helpful about TNF-α helps in improving psoriasis associated comorbidities in the lasting(Patel T et.al, 2004).

Role of T-cells:

According to the 1990s report, Psoriasis a disorder of fabrication of keratinocyte &their demarcation(Simen et.al, 2006) particularly epidermal hyperplasia which brings the generally embossed scientific and ancient characteristic. A mediated T-cell autoimmune disorder that come to mindcommencing the achievement of T-cell targeted therapies for instance Cyclosporine(Tyring S et.al, 2006 & Krueger GG et.al, 1984)& Tacrolimus(Ellis et.al, 1986)which have been engaged in the management of psoriasis (Baker et.al, 1987) and particular monoclonal antibodies employed &designed meant for CD3 and CD4 management for Psoriasis, while furtherdiscriminatory biological T-cell antagonists were created &experimentalenhancement in several patients with brutal Psoriasis. Further, antimetabolites use together with methotrexate which constraint epidermal hyper proliferation showed succeeding documentation from quantifiable learning and representation researchin-vitroandin-vivoresults maintain the ideathat Psoriasis is a T-cell mediated inflammatory skin ailment (Jegasothy et.al, 2016). Another conclusive study includes the testing interleukin-2 (IL- 2) diphtheria toxin fusion protein in Psoriasis patients (Prinz J et.al, 1991) and this mediatorwas recommended to decrease the triggered T cells express IL-2 receptors from Psoriasis skin lesions and resulted in scientific& histopathological changes in Psoriasis vulgaris. Likewise organization as long as another fusion protein, cytotoxic T-lymphocyte antigen-4 (CTLA4)-immunoglobulin, these were exposedtowardsturn round& improve the experimental and cellular description of psoriasis(Gottlieb SL et.al, 1995) which eventually blocks the T cell activation act as a go-betweenthrough dendritic cells (DCs) but does not precisely destroyed. All these studies accelerated greater exploration interested in the expansion of T-cell targeted drugs intended for Psoriasis.

Role of the IL-23/Th-17 axis:

IL-23/Th-17 is a new area in Psoriatic pathophysiology and the expansion, categorization, and behavior about to Th17 cells & IL-23 role in Th17 cell vulnerable persistent as peration in Psoriasis have been freshly reported (Abrams JR et.al, 1999). A heterodimeric cytokine IL-23 which subside that the protein IL-23p19 sub-unit combined with IL-12p40 sub-unit, an IL-12 subunit and this was revealedtowardsact as a go-between epidermal hyperplasia, acanthosis, and ortho hyperkeratosis via TNF-a, IL-20R2 and IL-22(Oppmann B et.al,2000) &(Chan JR et.al, 2006). Additionally, the IL-23task in psoriasis pathophysiology waspowerfully supported through the experimental conclusions which demonstrate with the intention of anti-TNF-α agents can diminish IL-23p19 and IL-12p40 mRNA levels &decline levels of IL-23 induced by cyclosporine A, UV therapy,and biological representativeassociate to experimentalenhancement in Psoriasis patient.

3. Treatment Approaches of Psoriasis

Topical Therapies:

Long-term establishedmanagement is measured to be the secureopportunity& is broadlysecond-handmeant for mild Psoriasis go after the systemic & light related remedies which have been used for the management of limited tooharsh Psoriasis. Long-termmanagement like (creams, lotions, gels, ointments, moisturizers applied to the skin) are usually the first line management and they help to reduce the accelerated production of skin cells and inflammation. List of topical drugs used in the treatment of Psoriasis along with their mechanism of action, side effect.

Systemic Therapies:

USFDA approved systemic treatment includes MTX, retinoid & cyclosporine whereas former drugs consist of mycophenolate, mofetil, hydroxyurea, 6-thioguanine & sulfasalazine that are directed systemically. Methotrexate is anti-inflammatory & immunosuppressant action due to which is principallyadvantageous for patients having Psoriatic arthritis disease and it is designate in the extendedperiodsupervision of pustular psoriasis, psoriasis erythroderma. It also provides some side effects like hepatic fibrosis, pulmonary fibrosis. Patients with psoriasis disease were untreatable towards long-term established healing remedies and towards previous modalities alike phototherapy, methotrexatefrequentlyuseful. Another systemic drug acitretin which also have been used in the normalization of keratinocyte proliferation and enhances in cellular differentiation and their long-term management in erythroderma and psoriatic arthritis in Psoriatic patients which brought side effects like pruritus, hyperglycaemia. Cyclosporine initiated intended on behalf of avoidance as long as rejection of kidney resettle in the 1970s. As cyclosporine is an immunosuppressive agent, has brought out the side effects in the skin like non melanoma skin cancer and it is used for the effectively for the treatment of psoriasis.Also,Retinoids which have also been reported highly effective over the pustular psoriasis, slowly effective over plaque & guttate psoriasis. Etretinate (retinoid derivative) is also use in the treatment of Psoriasis but ittime-consuming risk during teratogenicity women of childbearing so as a result acitretin was introduced with Etretinate which provide combination treatment with PUVA &UVB for Psoriasis treatment.

Cyclosporine is an immunosuppressive agent, and is contraindicated in patients with sensitive infections and in patients with active malice. It was tremendously efficient meant for all outward appearance about psoriasis. For temporary use, cyclosporine may be safer than methotrexate since bone marrow toxicity is not a matter. For Psoriasis the continuingmanagement of cyclosporine is undoubtedly toxic for nephrons. Oral tacrolimus (FK506) is another powerful immunosuppressive negotiator earlier which have been accepted&on behalf of the avoidance organ transplant rejection. Similar to cyclosporine, its mechanism is to inhibit T-cell activation; tacrolimus was dramatically effective in the treatment of psoriasis and it completely results83% diminution in Psoriasis Area and Severity Index (PASI) scores.Diarrhoea, paraesthesia, and insomnia were the side effects detailed in the treatment of Psoriatic patients.

Mycophenolate mofetil: During 1970s, mycophenolic acid wereexamineddesigned for the management of psoriasis, and a lot of patients accomplishextended position remissions with adequate side effects.A sign counting nausea, vomiting, and diarrhoea, waswidespread during the administration of Mycophenolate mofetil in the management of Psoriasis. It has also been worn for proven effectively for themanagement of variousprovocative or autoimmune skin disorders likepsoriasis vulgaris, and atopic dermatitis.

Hydroxyurea a different antimetabolite a particular have been used for the management of psoriasis for 3 decades. This can be usefulseeing that monotherapy, excludingalmost 50% of patients who attaindiscernibleenhancementand build up bone marrow toxicity with leukopenia or thrombocytopenia.6-Thioguanine a purine analogue to facilitate &accepted for the management of leukaemia and have been very muchsuccessful for psoriasis. There are mainly several other currently available medications which have been used in the treatment of psoriasis. Calcitriol colchicine, dapsone, propylthiouracilcan beuseful in assortment for Psoriatic patients. Carbamazepine has been described to do well to erythrodermic psoriasis.Fumaric acid esters have also been permitted for the management of psoriasis in Europe for more than a few years. PASI scores get better by up to 80%, howevera lot of patients put an end tomanagementas about to gastrointestinal side effects, together with abdominal pain and diarrhea as well as flushing. Sulfasalazine have also been recommended for the management of psoriasis.

Biologics:

Biologics are stated as folk'scommoditiesimitative from a living matter such as humans, plants, animals, or microorganisms for the management, avoidance, or alleviate human disease. According to the current medication available in support offair to brutal patients with Psoriasis disease have been found to be unproductive and results in cumulative end-organ toxicity and poor tolerability of drug used in systemic therapies.The goal of

these new therapies is to supply new selective, immunologically focussed innovation, so as to reduce adverse effects that are associated commonly with systemic therapies. The continuing use of biologics is additionallyworthwhile, because of improvedacceptability and wellbeing, buttherepriceis a majorconcern for their existense. These continuing biologics, living may be administer with the use of biosimilars as they charge cheaper and it is a biological drug, which is similar to a reference product that waspreviouslyaccepted and waslikely to have the similarprotection and worth living profile. Some biosimilar of infliximab and etanercept are also available andat last, their non-pharmacological routine innovations such as body weight declination in overweight patients are measuredto bring appropriateness in the world wide administration to Psoriatic patients.

The use of biologics in the treatment of Psoriasis has proved to beneficial about 25% of Psoriatic patients but patients suffering from Psoriatic arthritis were unable to cure alone with the use of biologics only 15 to 30% patients are cured. So these biologics were used in combination for the management of Psoriatic arthritis examples like Etanercept which have been worn in groupingwith other anti-inflammatory and immunosuppressive medications and other agents like Methotrexate, salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), or analgesics have also been available for their treatment. The addition of this biologic drug etanercept therapy direct to a noticeableprogress of disease activity in each patient, while patients with Psoriasis disease in the past showed disastrousact in response to monotherapy when managed with conventional agents. Etanercept and methotrexate have also been reported as a flourishingarrangement in the management of psoriasis and was notably better in the diminution of Psoriatic disease when compared with the disease when treated alone and further refusalsupplementary bone marrow toxicity or hepatotoxicity have also been reported from these combinations.

According to his article biologics are defined as proteins that hold pharmacologic activity and can be elicit from animal tissue or manufacturethroughout recombinant DNA techniques and their mechanisms have four approaches: diminution of pathogenic T cells, reticence of T-cell activation, immune variationandovercrowding the activity of inflammatory cytokines. Alefacept, efalizumab, etanercept, infliximab, andoprelvekin has been used as biologics which restrain the T-cell establishment and immigration, obstruct with the immune variation or obstruct the movement of inflammatory cytokines for mild to severe treatment for Psoriatic patients but these havebrought some side effects like **Cytokine release syndrome(CRS)** which have been detected in solid organ transplant patients when treated with biologics but having the majorityof widespreadunfavourable reactions, from these biologics more often than notrelated with the primarydosage of biologics, are headache, fever, chills, nausea or myalgia. So previous to the management, it is important that guideline laboratory tests werecarried out, together with hepatitis and HIV serology and also the tuberculin skin test.

Phototherapy:

According toPhototherapy, in the appearance of natural light, have been formulatedfor the use for thousands of lifetime for the advancement inplentiful skin disorder and is also measuredstronghold in the action as psoriasis and which was obtainable as psoralen plus UVA (PUVA), broadband UVB (BB-UVB), and narrowband UVB (NB-UVB). These therapies know how to be managedwithin the hospital, outpatient clinic, or at patient's home. The principle of these therapies to endowed with knowledge as well as some realisticsupervision to common dermatologists and inhabitants on the particulars of with phototherapy techniques,in spite of its diminishing use, ruinssingle about tolargelysecure and pricelessmanagement approaches for psoriasis. According to the article Targeted ultraviolet or ultraviolet physiotherapycounting Psoralen plus UVA, broadband UVB and narrow-band UVB and other devices forthe 308-nm excimer non laser & non-excimer light handheld devices which are successfulin support of psoriasis at the same time astight-fisteduncomplicatedskin confirmed about the sensitive and unendingdamagingthings of UV emission. However, these devices embraceunceasing (photoaging, skin cancer) and sensitive (sunburn, erythema) confineddeadlyspecial effectsrelated with UV irradiation. While UV light healing remedies are favourable for patients throughwidespread psoriasis, but the most importantrestrictionsconsist of highestamount of managementarrayon or after 25 to 30 towardsobviouswound& the qualified intolerance of the uncomplicatedmembranetowards UV exposure. Someasure up toby way of whole body phototherapy, the reward of subordinateincreasingdosage and smaller quantity of managementmight be connectedin the midst ofcompact carcinogenic and phototoxic risks. Cost-effectively, when evaluated with entire body phototherapy or biologics, localized phototherapy wasadditionallyreasonably priced for patients, known the smaller figureof management sessions. The advantages of localized phototherapy should be measuredamongst the managementselection for confined to a small areaof deviation of psoriasis, such as the plaque and palmoplantar pustular types. Psoriasisa chronic skin disease with the purpose ofmightnecessitate life-long intermittent management. Managementtypicallybeginby means ofrelevantmethod like local corticosteroids, calcipotriol, dithranol/anthralin/chignolin or coal tar was failed. In severe cases, phototherapy or systemic management can be applied. Introduction to syntheticwhole body phototherapy with ultraviolet B or with ultraviolet A or in mixture with psoralens (PUVA) wasat presentacknowledgedfor the management of Psoriasis. In adding together, orally administer drugs such as Methotrexate (MTX), Retinoids like acitretin (ACl) and its antecedent cyclosporine A (CYA) and grouping of the above mentionedmodalities are also obtainable for psoriasis management. A systematic literature review was done on the foundation of most oftenuseful systemic management in chronic plaque-type psoriasis, by means ofobservation to their ability to persuadediminution. PUVA treatment was

linked with the uppermoststandard reported percentage of patients throughapproval and the uppermostpercentage of patients amongsuperiorclassreaction, followed up by UVB and CYA, authorizationchargewerelesser or RET and CYA.



Figure 4: Types of Drug loaded nanocarrier diagrammatic representation

- Free drug enter the membrane and is instantaneously let go off. The drug at that moment spread throughout the membrane speedily, restraining membrane preservation & direct to useless assimilation into the blood which amplify the threat of universal surface effects.
- Drug-loaded nanocarriers leisurely enter the membrane; these form an elevated medicine concentration gradient at the membrane surface, gradually motivating the medicine keen on the membrane. Previously in the membrane, the nanocarrier can lodge in the lipid prevailing conditions along with gradual liberation the included drug leading to amplified medicine maintenance inside the membrane.

Nanocarriers based approaches used in the treatment of Psoriasis

Liposomes: These are stated as concentric bilayer vesicles made of phospholipid (composed of head and tail) in which the hydrophilic drug is entrapped in an aqueous core is enclosed by a membranous phospholipid bilayer and the hydrophobic drug is entrapped in lipophilic region. Its size range varies from 25-500nm.These liposomes helps in the stabilisation of unstable drugs and serve as penetration enhancer facilitating the transport of compounds which are unable to penetrate the skin. These liposomes facilitatefalling skin soreness by satisfying the discharge of drugs and by hydration of the epidermis. They as well have the greatestpossibility of aiming at certainsdrugs interested in the pilosebaceous structures and as a resultthey include an added advantage for management of hair follicle-associated disarray.

Knudsen concluded about the penetration of Calcipotriol liposomes were recovered than the lipid liposomes which signifying that at least a small part of drug is dischargedas of the liposomes throughoutimmigration in the skin tissues.

Srisuk revealed about the MTX liposomes containing cholesterol and oleic acid which showed enhancement in skin permeability and is further characterised by high concentration & Flux of MTX diffuse across the membrane.

Knudsen stated about the Calcipotriol liposomal gel and its liquid state formulation which good penetration from the liquid state formulation as compared to gel state liposomal formulation.

Ward concluded about the Clodoronate liposomes were injected into the mouse skin and this shows decreased dermal angiogenesis, APC cell depletion, immune cell infiltration & less cytokines production due to which it able to show reverse Psoriasis effect on mouse.

Nagledetermines about the antipsoriatic efficacy using mouse tail model. Also the formulation shows utmost drug withholding in the skin, disrupted epidermis & in-vitro studygive you an idea about parakeratosis which is a trait of Psoriasis.Bhatia brought out about the in-vitro cytotoxicity of Tamoxifen liposomal formulation and strong inhibition in the viability of epidermal keratinocyte cell formation in Psoriasis disease.Dragicevicstated about the rheological parameters, polydispersity index of Temoporfin liposomal formulation which doesn't show any remarkable changes and made them unacceptable for topic use.

Singh reveals about the elastic liposomal formulation which is 1.25 fold higher skin deposition than colchicine liposomal formulation and showed sustained biological effect, decreased in inflammatory cells accumulation & collagen deposition with elastic liposomal formulation than the drug solution.Ali reveals about the MTX hydrogel for the treatment of localizedPsoriasis for both LMTX &FMTX gelsproved zero order kinetics and anti-psoriatic activity and no analytical major changes were seen on the subject of blood or other laboratory variables in mouse skin.

Niosomes:

These are defined as colloidal vesicular carrier in drug delivery and formed at the top appertaining to non-ionic surfactant vesicles that are biodegradable & non-toxic. Thisamount cost effective &securewhen evaluateby means ofprevious colloid carriers. It has applications in oral, topical, parental & novel drug delivery as controlled and targeted delivery.

Nanoparticles: These colloidal particulate systems in the midst ofamount ranging startingamidst 10 nm to 1000 nm offer targeted drug delivery, sustained release, safety appertaining to labile groups as ofdreadful conditions, little toxicity and drug adhesivity inside themembrane. Drug contain nanocarriers, such as liposomes, micelles, polymeric & solid lipid nanoparticles, dendrimers, nanoemulsionsat the same time as inorganic nanoparticles and sub-micrometric emulsions are at present accessible.

The topically useful NP disseminateright the way through the epidermis and dermiscontained by the following days and showed a significant reduction in the discharge of provocative cytokines like IL–1, IL–6, IL–8, IL–20 and IL–23 and no cytotoxicity was perceived in Psoriatic lesions. These lipid nanoparticles alsocapabletowardsaugmenting dosagepenetration within the membrane, agreed toamplify targeting towards the outer layer of the membrane &as a resultmounting treatment effectiveness as well asfalling the systemic amalgamation of drugs and cosmetic actives. The complete degradation among lipid nanoparticles & their well-matched chemical environment have opened the designate of nanosafe carriers.The SLN-chitosan-TRE show

sign of elevated encapsulation effectiveness, elevated physical steadiness contained by the tested period (one year), was no more cytotoxic to keratinocytes &give you an idea about high antisepticactionnext to P. acnes and S. aureus. As a result chitosan-SLN be capable ofhigh-qualityapplicanttowardssummarize TRE in addition to augment ownbeneficialeffectiveness in the long- term establishedmanagement of pimples.

Monostearin SLN demonstratedoutstanding controlled release properties and a significant epidermis drug reservoir whereas, beeswax SLN might not lessen the drug penetrationall the way through the skin, nor augment the drug substance in the upper layers of the skin. The dispersal of corticosteroids into the skin emerge to be reliant on the lipid formulation of the monostearin SLN and these current SLN products offerhugeprobability for taken care of dermatological conditions by aiming at an objective corticosteroids to epidermal/upper dermal disease sites while diminish systemic drug absorption.

Hydrogels enclosednanoencapsulated tretinoin confirmedminor light destruction (24.17 ± 3.49%) former at that time the compositionsurrounded by the non-encapsulated drug (68.64 ± 2.92%) following 8 h of ultraviolet A irradiation. The half-life ofprevious will be seven times superiortowards the last. There will bedeclineinside the membrane permeation coefficient of the drug by nano-encapsulation, separately the prescribed amounttype.



Figure 5

Table 1: Topical Therapies

Drug	Mechanism of action	Side effect	Uses	Reference
Dithranol	Anti-proliferative effect	Soreness & discoloration to the skin, nails & clothing.	For treating mild to moderate Psoriasis.	Fuchs et al 1990
Coal tar	DNA suppression	Smell, irritation, staining of clothes	For mild, moderate & severe Psoriasis.	Walter et al, 1978
Topical corticosteroids	Anti-inflammatory & immunosuppressant	Flaming skin, deteriorate, Photosensitivity, & skin soreness.	For Cutaneous plaques, lesions on the palms, soles.	Lebwohl et al, 2005
Tacromlimus	Immunosuppressant	Flaming, skin cancer & lymphoma.	For mild & moderate plaques.	Scheinfeld et al 2004
Tazarotene	Anti-proliferative & anti- inflammatory	Pruritis, erythema, flaming and	For mild treatment of Psoriasis	Weinstein et al, 2003

		desquamation.		
Topical Vit D analogues	Keratinocyte propagation	Irritation and hypercalcemia	For severe plaques of Psoriasis.	Takahashi et al 2003

Table 2: Recent reports on liposomal formulation for the treatment of Psoriasis

Carriers	Drug	Remark/Application	Reference
Liposomes		The topical appliance of liposomal gels on imiquimod induced psoriatic plaque model illustrates contractionsignals of psoriasis andstage of cytokines like TNF-α, IL-17 and IL-22.	Doppalaudi et.al, 2017
	MTX	MTX with liposomal formulation, niosomal gel, hydrogel, albumin conjugates, nanoparticles and nano structured lipid carriers were found to be successfully come up for the treatment in Psoriasis & RA are also reviewed.	Rajitha Pet.al,2017
	Madecassoside	MA double-emulsion liposomes confirmedbetter-qualitysteadiness and homogeneous outward show and also to augment transdermal and lesionscurativeeffect.	Li Z et.al,2016
	Cyclosporine (Cys)	Cys shows 16% complete clearance in Psoriatic lesions sites but when Cyslipogel when treated with Clobetasol propionate shows 85.7% complete clearance.	Kumar R et al, 2016
	Cyclosporine (Cys)	Theformulated lipoplexes was tointernalize hooked onto melanoma cells which hit down the appearance of the BRAF protein and bring about cell death in melanoma cells by fluorescent microscopy, in-cell immunofluorescence assess and WST-1 cell propagationassess	Dorrani M et.al,2016
	Fusidic acid	FA-LP in-vivo studies were done using the mouse tail model. This FA- LP originatedto be extensivelybetter than conventional one with enhancedeffectiveness in and around the target site.	Wadhwa S et.al, 2016
	Capsaicin	Skin maintenance studies of CAP from in-vitro and in-vivo experimentationmade knownappreciablyelevatedamassing of drug in case of emulgelformulation from previous formulation like liposomes, niosomes.	Gupta R,et.al,2016
	Tamoxifen-FMVs	Anti-psoriatic activity was estimated on mice tail showednotablyelevatedefficiency of TAM–FMV gel then other formulations.	Bhatia A et.al, 2014

Table 3: Nisomal Therapy

Carriers	Drug	Remark/Application	Reference
Niosomes	Acetretin	This topical formulation also helps in reduction in epidermal thickness, highest orthokeratosis, and drug active in mouse tail model.	Abu Hashim et.al,2018
	MTX	MTX loaded niosomes showed vesicle high entrapment efficiency and zeta potential at Cholesterol &application of 30% and 23.6%, correspondingly when Glycerol was employed as the solvent	Zidan AS et.al, 2017
	Diacerin	The confocal laser scanning microscopy demonstratedwith the purpose ofniosomesput emphasis on the diffusion of diacerein into the epidermal & dermal layer of rat skin.	Moghddam et.al, 2016
	MTX	The In-vivo skin authentication study also give you an idea about the maximumgain of	Abdelbary et.al,2015

		drug set down&maximum AUC of MTX on or afterniosomes were considerablybetter than a certain drug solution	
	Tretinoin	This formula shows elevatedeffectiveness& very littlefrustrationlikely when match up toto marketed product in human volunteers.	Rahman SA et.al,2014
	Ammonium Glycyrrhizinate	The AG-loaded non-ionic surfactant vesicles give you an idea aboutdenialtoxicity, good skin acceptability&proficientenough direct towardsrecuperateof the anti-inflammatory movement in mice.	Marianecci C et.al,2014

Table 4: Recent approaches for the Treatment of Psoriasis

Carriers	Drug	Remark/Application	Reference
Nanoparticles	Thymol	This formulation was tested in an imiquimod – induced psoriasis mouse model & showed improved healing.	Pivetta et.al, 2018
Micelles		These micellesknow how toaugment the therapeutic usefulness and diminish the systemic side effects of the drugs and also the evidence of drugs in besieged sites of the skin in the normal and dermatological diseases such as psoriasis and acne	Behzad et.al, 2018
	Ploylactic acid	In-vivo studies conducted on mice for 8days & less skin irritation from the two formulation. Ex-vivo studies including permeation through diffusion cell was decreased but when compared with the PLA NPssuspension and the penetration profile was not significantly different.	Boisgard et.al 2017
		The activity of FK506 NPs–NIC was assessed throughoutthe management for imiquimod (IMQ)-induced psoriasis also showed a synergistic effect on anti-psoriasis which eventually augmented the beneficialoutcome and diminish the systemic side effects by dropping the largelydosage of FK506.	Wan et.al,2017
	MTX & Etanercept	Pig ear model is used for permeation studies which showed skin deposition of MTX in relation the free drug.	Ferreira et.al,2017
	Curcumin	These CUR-NPs-gel thereforecapable to slow up the appearance of inflammatory cytokines (TNF-α, NF-κB and IL-6) to a largeramount.	Mao et.al,2017
		Nanoparticle of dissimilar carriers make possiblereview of transdermal drug delivery which gives you an idea concerningdissimilarways to augment skin diffusion, well-built hydrophilic drugs and for syndromemanagement, vaccination whichillustratesvictorious application in greater than beforedissemination of drugs or vaccines, control drug release and under attack drugs to accurateregion of skin in-vivo.	Palmer et.al,2016
	Spherical nucleic acid Gold Nanoparticles.	In vitro experiments indicated that siRNAs combined with spherical nucleic acid gold nanoparticles be able toextensivelydiminish gene expression in cells and in-vivo trial	Nemati et.al, 2017

		which give you an idea about the topical function of siRNAs get across by SNA-NCs throughout the skin can appreciablyhold back the propagation of cells.	
SLN & NLC		The anti-psoriatic efficacy in BALB/c mice (evaluated on basis of cytokine levels and skin morphology) featured the potential of drug-loaded NLC significantly higher as compared to drug loaded SLN and marketed formulation Betagel	Arora et.al, 2017
Nanoemulsion	Clobetasol Propionate &Calcipotriol	Imiquimod induced psoriatic BALB/c mice model approveda large amountof elevated anti-psoriatic activity of nanoemulsion gel as contrast to free drugs and marketed formulation. For that reasonindustrial preparationconfirmirrelevant skin irritation in-spite of amplifieddispersion into the skin.	Kaur A et.al,2017
	Triamcinolone acetonide	In vitro skin allotment study showed verified systemic break out of drug from TA loaded SLNs which powersto eradicate side-effects relatedby means ofcompleteintroduction.	Pradhan et.al, 2016
	MTX	In vitro studies showed that Methotrexate combined with Au3MPS &to a great extentdemonstrated extraresourceful than Methotrexate alone. Furthermore the non-appearance of the Au-3MPS in the dermis and in the epidermis region recommend that the skin do not hold on to the nanoparticles.	Bessar et.al, 2016
Nanostructured lipid carriers	Flucinoloneacetonide	FA in the epidermis powers toget rid ofundesirable after-effects coupled with systemic contact which may perhaps a possible system for psoriasis management.	Pradhan et.al, 2015
	MTX	In vitro skin dissemination study established that methotrexate-loaded NLCs-P60 haveelevated skin diffusionwhilstmatch up to free methotrexate, portentous a remarkable role of drug-nanocarriers on topical management.	Pinto et.al,2015
Micelles	Zinc Phthalocyamine	ZPB nanostructure was investeigated using a guinea pig psoriasis model the amalgamation of light and ZPB give you an idea regarding the best photodynamic management for psoriasis, support on the light excitation of the photosensitizer ZPB and the psoriasis was initiated to be almostheal according to the histopathological examination	Jin Y et.al, 2015
Nanocapsules	Dithranol	The dithranol-loaded lipid-core nanocapsules give you an idea aboutdescription of drug content close up to the theoretical application, enhanced encapsulation effectiveness, nano-size range, and good zeta size values.	Savian et.al, 2015
	Tacrolimus	Skin penetration and preservation study has acknowledge a noteworthyamplifythe quantity of tacrolimus pervaded and engaged	Thapa et.al, 2014

		by the use of LCNs. Tacrolimus loaded LCNs are additionallysuccessful in the management of psoriasis like skin soreness.	
Micelles	Tacrolimus A	The micelles were found to stable for stable over a period of 7months and it showied the biodistribution profile without increasing the systemic profile and reduce the side effects in the cutaneous region of the skin	Lapteva et.al, 2014
	Capsaicin	The increasingquantity of CAP get effortlesslyinfuse through the skin and maintained in the SC were superior in case of NLCs as evaluatein the midst of plain drug solution and SLNs.	Agarwal et.al,2013
Nanolipoidalcarreirs	Tretinoin	Nanoparticulate carriers (SLNs, NLCs) presentedimproved photo stability, skin transport and anti-psoriatic activity equivalentby way ofvesicular carriers (liposomes, ethosomes) and the marketplace product were commence to be supplementary biocompatible and successful than the marketplace product.	Raza K et.al,2013
Dendrimers	Dithranol	DIT-PPI illustratesimprovedpenetrationspeed& lesser skin exasperation when compared with DIT solution.	Agarwal U et.al, 2013

4. Conclusion

Psoriasis is a vulnerable, inflamed, auto-immune mediated t-cell skin disorder which leads to redness, itchy silvery patches on the skin. The treatment for such inflamed, recurrent disorder include topical, systemic, biologics, phototherapy which are available and able to give relief to patients with moderate to severe & mild to moderate disease but at some point this disease was not completely eradicated, actually it reoccurs due to genetic disposition & T-cell markers present on T-cell. As the word Nanotechnology offers encourages dosage release toward advance newsworthy, systemic & other management. Nanocarriers such as liposomes, niosomes, micelles, solid lipid nanoparticles, nanostructure lipid capsules, dendrimers have been successfully employed for the Psoriatic patients. Studies with these nanocarriers also characterize or else scrutinize for membrane diffusion to a certain extent than anti-psoriatic effectiveness & appeared to be safe, able to enhance efficacy & reduce side effects of the incorporated dosage from beginning to end enhanced membrane preservation, sustained released & diminish complete assimilation. Also some animal models like imiquimod, murine models have been used for anti-psoriatic therapy containing nano-formulation but these are not generalized to humans as Psoriasis doesn't occurred in mice. The results using these formulations may able to enhance effectiveness attributed to their incorporated dose throughout membrane preservation & sustained release of the drug, diminishes medicine incorporation & also limited systemic toxicities. Few studies have been compared with each other containing nano formulations that showed good potential but the results might be drug specific. Some personalized therapies for the pathogenesis of Psoriasis have been successfully employed through the topically useful SiRNAs formulation which probably showed the increase of beneficial effectiveness. But the information, more searches is needed on Nano formulation so as to optimize & commercialize such therapies for clinical use of Psoriasis.

5. References

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. Journal of the American Academy of Dermatology. 2002 Jan 1;46(1):1-26.
2. Marchetti A, Feldman SR, Kimball AB, Anderson RR, Miller LH, Martin J, An P. Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. Dermatology online journal. 2005 Jan 1;11(1).
3. Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. Journal of dermatological science. 2012 Jan 1;65(1):4-11.
4. Pradhan M, Singh D, Singh MR. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. Journal of controlled release. 2013 Sep 28;170(3):380-95.
5. Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Human molecular genetics. 1998 Sep 1;7(10):1537-45.

6. Ram S. Indian psoriasis research: An impact assessment through bibliometric studies. Journal of Scientometric Research. 2013 May 1;2(2):126-31.
7. Boehncke WH. Etiology and pathogenesis of psoriasis. Rheumatic Disease Clinics. 2015 Nov 1;41(4):665-75.
8. Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN, Mule PM. Psoriasis: A comprehensive review. International Journal of Pharmacy & Life Sciences. 2011 Jun 1;2(6).
9. Baerveldt EM. Psoriasis: Molecular targets of denervation and therapy. 2013 Feb 13.
10. Dubois Declercq S, Pouliot R. Promising new treatments for psoriasis. The Scientific World Journal. 2013; 2013.
11. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P. Mechanisms of action of topical corticosteroids in psoriasis. International journal of endocrinology. 2012; 2012.
12. Su YH, Fang JY. Drug delivery and formulations for the topical treatment of psoriasis. Expert opinion on drug delivery. 2008 Feb 1;5(2):235-49.
13. Mahé E, Maccari F, Beauchet A, Lahfa M, Barthelemy H, Reguiaï Z, Beneton N, Estève E, Chaby G, Ruer-Mulard M, Steiner HG. Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. British Journal of Dermatology. 2013 Oct 1; 169(4):889-95.
14. Miteva M, Tosti A. Hair and scalp dermatoscopy. Journal of the American Academy of Dermatology. 2012 Nov 1; 67(5):1040-8.
15. Gordon-Elliott JS, Muskin PR. Managing the patient with psychiatric issues in dermatologic practice. Clinics in dermatology. 2013 Jan 1; 31(1):3-10.
16. Fraga NA, Oliveira MD, Follador I, Rocha BD, Rêgo VR. Psoriasis and uveitis: a literature review. Anais brasileiros de dermatologia. 2012 Dec; 87(6):877-83.
17. Garg N, Truong B, Ku JH, Devere TS, Ehst BD, Blauvelt A, Deodhar AA. A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. Clinical rheumatology. 2015 Oct 1; 34(10):1745-51.
18. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Annals of the rheumatic diseases. 2005 Mar 1; 64(suppl 2):ii18-23.
19. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology. 2009 Jun 1;129(6):1339-50.
20. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Current rheumatology reports. 2007 Dec 1;9(6):461-7.
21. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Archives of Dermatology. 2001 Mar 1;137(3):280-4.
22. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011 Feb 25;34(2):149-62.
23. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. Journal of Investigative Dermatology. 2004 Dec 1;123(6):1037-44.
24. Ma HM, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Fouser L. IL-22 is Required for Th17 Cell Mediated Skin Inflammation in Murine Model of Psoriasis. Clinical Immunology. 2008 Jan 1;127:S3.
25. Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas dermo-sifiliograficas. 2009 Dec 1;100:2-13.
26. Gottlieb A, Frederick B, Everitt D, Mccormick T. A phase 1 study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 P40 antibody administered subcutaneously in subjects with plaque psoriasis. Journal of the American Academy of Dermatology. 2005 Mar 1;52(3):P172.
27. Barrie III AM, Plevy SE. The interleukin-12 family of cytokines: Therapeutic targets for inflammatory disease mediation. Clinical and Applied Immunology Reviews. 2005 Jul 1;5(4):225-40.
28. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nature medicine. 2003 Jan;9(1):40.
29. Rahman M, Akhter S, Ahmad J, Ahmad MZ, Beg S, Ahmad FJ. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert opinion on drug delivery. 2015 Apr 3;12(4):635-52.
30. Asadullah K, Döcke WD, Ebeling M, Friedrich M, Belbe G, Audring H, Volk HD, Sterry W. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Archives of dermatology. 1999 Feb 1; 135(2):187-92.
31. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'Type 1'inflammatory gene expression. Trends in immunology. 2004 Jun 1;25(6):295-305.
32. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as monotherapy in patients with psoriasis. New England Journal of Medicine. 2003 Nov 20;349(21):2014-22.

33. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. The Lancet. 2001 Jun 9;357(9271):1842-7.
34. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatologic therapy. 2004 Oct 1;17(5):427-31.
35. Simen BB, Duman CH, Simen AA, Duman RS. TNFα signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biological psychiatry. 2006 May 1;59(9):775-85.
36. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. The Lancet. 2006 Jan 7;367(9504):29-35.
37. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weins-tein GD. Psoriasis. J Am Acad Dermatol. 1984;11:937-47.
38. Ellis CN, Gupta A, Griffiths CE. Cyclosporine Improves Psoriasis. Jama. 1986;256:3110-6.
39. BAKER BS, Griffiths CE, Lambert S, Powles AV, Leonard JN, Valdimarsson H, Fry L. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. British Journal of Dermatology. 1987 Apr 1;116(4):503-10.
40. Jegasothy BV, Ackerman CD. Tacrolimus (FK 506)\p= m-\ANew Therapeutic. Arch Dermatol. 1992;128:781-5.
41. Prinz J, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber P, Riethmüller G. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. The Lancet. 1991 Aug 3;338(8762):320-1.
42. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature medicine. 1995 May 1;1(5):442-7.
43. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. The Journal of clinical investigation. 1999 May 1;103(9):1243-52.
44. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov 1;13(5):715-25.
45. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, Gorman DM. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis. Journal of Experimental Medicine. 2006 Nov 27;203(12):2577-87.
46. Feldman SR, Tian H, Gilloteau I, Mollon P, Shu M. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective US database. BMC health services research. 2017 Dec;17(1):337.
47. Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. International journal of molecular sciences. 2017 Nov 16;18(11):2427.
48. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. British Journal of Dermatology. 1997 Dec 1;137(6):943-9.
49. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New England Journal of Medicine. 2007 Feb 8;356(6):580-92.
50. Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. Journal of the American Academy of Dermatology. 2011 May 1;64(5):936-49.
51. Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatology online journal. 2012 Oct 1;18(10).
52. Mudigonda T, Dabade TS, Feldman SR. A review of targeted ultraviolet B phototherapy for psoriasis. Journal of the American Academy of Dermatology. 2012 Apr 1;66(4):664-72.
53. Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Medical Science Monitor. 2008 Dec 1;14(12):PI66-74.
54. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. Journal of dermatological treatment. 2007 Jan 1;18(1):40-5.
55. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. International journal of pharmaceutics. 2004 Feb 11;270(1-2):119-25.
56. Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: a new paradigm in the treatment of chronic plaque psoriasis. Drug delivery. 2016 May 3;23(4):1204-13.
57. Kumar R, Dogra S, Amarji B, Singh B, Kumar S, Vinay K, Mahajan R, Katare OP. Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial. JAMA dermatology. 2016 Jul 1;152(7):807-15.

58. Desmet E, Bracke S, Forier K, Taevernier L, Stuart MC, De Spiegeleer B, Raemdonck K, Van Gele M, Lambert J. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: proof-of-concept in the treatment of psoriasis. International journal of pharmaceutics. 2016 Mar 16;500(1-2):268-74.
59. Abdelbary AA, AbouGhaly MH. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box–Behnken design, in-vitro evaluation and in-vivo skin deposition study. International journal of pharmaceutics. 2015 May 15;485(1-2):235-43.
60. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artificial cells, nanomedicine, and biotechnology. 2014 Dec 1;42(6):406-12.
61. Tomar S, Singhal T. Formulation and Evaluation of Topical Gel Containing Azithromycin and Prednisolone Vesicles for Treating Psoriasis. International Journal of Pharmaceutical Research & Allied Sciences. 2015;4(4):45-58.
62. Bessar H, Venditti I, Benassi L, Vaschieri C, Azzoni P, Pellacani G, Magnoni C, Botti E, Casagrande V, Federici M, Costanzo A. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids and Surfaces B: Biointerfaces. 2016 May 1;141:141-7.
63. Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Molecular pharmaceutics. 2014 Aug 5;11(9):2989-3001.
64. Zhang YT, Shen LN, Wu ZH, Zhao JH, Feng NP. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy. International journal of pharmaceutics. 2014 Aug 25;471(1-2):449-52.
65. Gupta R, Gupta M, Mangal S, Agrawal U, Vyas SP. Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy. Artificial cells, nanomedicine, and biotechnology. 2016 Apr 2;44(3):825-34.
66. Zhang YT, Shen LN, Wu ZH, Zhao JH, Feng NP. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy. International journal of pharmaceutics. 2014 Aug 25;471(1-2):449-52.
67. Avasatthi V, Pawar H, Dora CP, Bansod P, Gill MS, Suresh S. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation. Pharmaceutical development and technology. 2016 Jul 3;21(5):554-62.
68. Pinto MF, Moura CC, Nunes C, Segundo MA, Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. International journal of pharmaceutics. 2014 Dec 30;477(1-2):519-26.
69. Nasr M, Abdel-Hamid S, H Moftah N, Fadel M, AAlyoussef A. Jojoba Oil Soft Colloidal Nanocarrier of a Synthetic Retinoid: Preparation, Characterization and Clinical Efficacy in Psoriatic Patients. Current drug delivery. 2017 May 1;14(3):426-32.
70. Gungor S, Rezigue M. Nanocarriers mediated topical drug delivery for psoriasis treatment. Current drug metabolism. 2017 May 1;18(5):454-68.
71. Depieri LV, Borgheti-Cardoso LN, Campos PM, Otaguiri KK, de Carvalho Vicentini FT, Lopes LB, Fonseca MJ, Bentley MV. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase. European Journal of Pharmaceutics and Biopharmaceutics. 2016 Aug 1;105:50-8.
72. Baboota S, Alam MS, Sharma S, Sahni JK, Kumar A, Ali J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. International journal of pharmaceutical investigation. 2011 Jul;1(3):139.
73. Palmer BC, DeLouise LA. Nanoparticle-enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules. 2016 Dec 15;21(12):1719.
74. Marepally S, Boakye CH, Patel AR, Godugu C, Doddapaneni R, Desai PR, Singh M. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine. 2014;9(14):2157-74.
75. Lohan SB, Bauersachs S, Ahlberg S, Baisaeng N, Keck CM, Müller RH, Witte E, Wolk K, Hackbarth S, Röder B, Lademann J. Ultra-small lipid nanoparticles promote the penetration of coenzyme Q10 in skin cells and counteract oxidative stress. European Journal of Pharmaceutics and Biopharmaceutics. 2015 Jan 1;89:201-7.
76. Thapa RK, Yoo BK. Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. Journal of Dermatological Treatment. 2014 Feb 1;25(1):22-5.
77. Pradhan M, Singh D, Singh MR. Development characterization and skin permeating potential of lipid based novel delivery system for topical treatment of psoriasis. Chemistry and physics of lipids. 2015 Feb 28;186:9-16.
78. Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert opinion on drug delivery. 2014 Dec 1;11(12):1833-47.
79. Madan JR, Khude PA, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. International journal of pharmaceutical investigation. 2014 Apr;4(2):60.

80. Morales JO, Valdés K, Morales J, Oyarzun-Ampuero F. Lipid nanoparticles for the topical delivery of retinoids and derivatives. Nanomedicine. 2015 Jan;10(2):253-69.